A 16-week comparison of the novel insulin analog
insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog
lispro in variable combination with NPH insulin at mealtime.
A recent comparison (33-35) of premixed insulin analogs
vs premixed human insulin formulations suggests similar effectiveness in lowering A1C and FPG levels, but superior effectiveness for premixed analogs in lowering PPG levels (TABLE 1).
Raskin P, Guthrie RA, Leiter L, et al: Use of insulin aspart, a fast-acting insulin analog
, as the mealtime insulin in the management of patients with type 1 diabetes.
The total dose of rapid-acting insulin analog
is divided, with 38% delivered at breakfast, 28% at lunch, and 33% at dinner (White RD, et al.
The characteristics of insulin that contribute to variable efficacy, high risk for hypoglycemia, and weight gain can all be reduced by substituting long- and rapid-acting insulin analogs
for NPH and regular human insulin, respectively.
According to the company, the two Phase III clinical trials for insulin analog
programme are already underway.
A third insulin analog
on the market, insulin glulisine (Apidra), approved in 2004, has a pharmacokinetic profile that is similar to insulin aspart and lispro, but Mr.
Within the last decade, newer insulin analogs
have become available to replace standard insulin formulations and novel agents and delivery devices have been developed.
Intrapatient insulin absorption can be highly variable and this study evaluates and quantifies the ability of PH20 to produce a more consistent PK profile relative to the PK variability produced by the insulin analog
Various insulin analog
formulations allow for improved basal or postprandial coverage, while premixed formulations provide control for both.
Tailored insulin analogs
and other long-acting insulins for injection with drug delivery solutions aim at optimized pharmacokinetic profiles in order to avoid hyper- and hypo-glycemic episodes.